Biotech company Pharming Group NV announces a new analyst report from Roth Capital Partners.

PHARM.AS: Increased Ruconest Focus Should Drive Upside

Visit our Analyst Coverage & Reports page to read more reports by ROTH Capital Partners.

Contact

Sijmen de Vries, CEO: T: +31 524 7400

“This update is for informational purposes only and is not viewed by Pharming to be of a price sensitive nature”

print